Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg

Click to increase image sizeClick to decrease image size

Abbreviations

BMI, body mass index

FDA, US Food and Drug Administration

GLP-1, glucagon-like peptide-1

GLP-1RA, glucagon-like peptide-1 receptor agonist

HbA_1c, glycated hemoglobin

IBT, intensive behavioral therapy

OW, once weekly

PCP, primary care practitioner

QoL, quality of life

STEP, Semaglutide Treatment Effect in People with obesity

T2D, type 2 diabetes

Acknowledgments

Medical writing and editorial support were provided by Nicole Cash, PhD, of Axis, a division of Spirit Medical Communications Group Limited, and Peter Birch, MA, CMPP, a contract writer working on behalf of Axis (and were funded by Novo Nordisk Inc.), under the direction of the authors. Novo Nordisk Inc. also performed a medical accuracy review.

Declaration of financial/other relationships

Janine V. Kyrillos: honoraria for non-promotional talks – Novo Nordisk, and fees from Eli Lilly for participation in a US Medical Education Obesity Advisory Board.

Patrick M. O’Neil: research grants to his university – Eli Lilly, Epitomee Medical, Novo Nordisk, and WW International; fees for consulting or advisory board participation – Gedeon Richter and Pfizer; and honoraria for non-promotional talks – Novo Nordisk and Robard.

Sean Wharton: research funding, advisory/consulting fees, and/or other support – AstraZeneca, Bausch Health Inc., Boehringer Ingelheim, CIHR, Janssen, Lilly, and Novo Nordisk.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This peer-reviewed article was supported by Novo Nordisk Inc.; the company was provided with the opportunity to perform a medical accuracy review.